PHARMACIA ON INT'L OFFERING ROADSHOW

12 June 1994

Swedish drug company Pharmacia, which is currently touring 20 cities on its roadshow for its global privatization offering, was in London last week. The Swedish government is offering up to 72 million A shares of the total 98.2 million A shares it holds. The government also holds just under 17 million B shares. There will be 32 million shares available for the international offering, including 10 million to be available in the USA, and 40 million for the Swedish public offering, with the proviso that the international offering can be reduced by 7.5 million shares in order to increase the Swedish allocation.

Retail applications for shares started on June 1 and ended June 10, and the final size of the offering will be determined on June 16. This and the offering price is expected to be announced on June 17.

Speaking about the government's privatization of the company in London last week, Jan Eckberg, chief executive of Pharmacia, said: "we are very pleased to have reached this point as we have been living with uncertainties in structure for the past two years." He said that it is important for a company to have stability in its shareholding, strategy and management.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight